{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-000110","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2023-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.619320+00:00","generated_at":"2026-06-20T20:32:11.762272+00:00","sec_items":["3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Tenax Therapeutics effects 1-for-20 reverse stock split to meet Nasdaq minimum bid price","bullets":["Reverse stock split at 1-for-20 ratio effective 5:00 p.m. ET on January 4, 2023.","Shares outstanding reduced from 45,836,215 to approximately 2,291,811; no fractional shares issued, rounded up.","Stock to trade split-adjusted on Nasdaq under symbol TENX starting January 5, 2023; new CUSIP 88032L506.","Reverse split was approved by shareholders on June 9, 2022; board set ratio on December 15, 2022.","Purpose is to regain compliance with Nasdaq's minimum $1.00 bid price requirement for continued listing."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-000110","json":"https://secwatch.observer/filing/0001654954-23-000110.json","markdown":"https://secwatch.observer/filing/0001654954-23-000110.md","text":"https://secwatch.observer/filing/0001654954-23-000110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495423000110/0001654954-23-000110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495423000110/tenx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T20:32:11.762272+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"42a2f249fbe74746fb0a105851a97a905c31115c","claim":"TENAX THERAPEUTICS, INC.: Certificate of Amendment filed to effect reverse stock split of common stock at 1-for-20 ratio (effective 2023-01-04).","evidence_excerpt":"Tenax Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Certificate of Incorporation, as amended (the “Certificate of Amendment”) with the Secretary of State of Delaware for the purpose of effecting a reverse stock split (the “Reverse Stock Split”) of the outstanding shares of the Company’s common stock at a ratio of one share for every 20 shares outstanding","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000165495423000110/0001654954-23-000110-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-01-04"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}